1. Medtech Insight
  2. >>Archive

PODCAST: Masimo CEO Bets Smart Glasses Are The Future Of Patient Monitoring

When Masimo chairman and CEO Joe Kiani saw Atheer's smart glasses and virtual reality platform, he thought the possibilities for patient monitoring were endless. Now the two companies have joined forces and are moving quickly to turn virtual reality into a clinical reality with a prototype interactive display and novel patient monitoring system that they say has the power to transform health care and the market for patient monitoring, which is estimated at more than $2 billion in the US alone according to an upcoming report from Medtech Insight.

Irvine, CA-based Masimo Corp., a market leader in pulse oximetry and other non-invasive patient monitoring technologies, and augmented-interactive reality company Atheer Labs unveiled a prototype app and information display at the American Society of Anesthesiologists (ASA) annual conference in San Diego in October that uses virtual reality, see-through smart glasses and touch-free controls to allow clinicians to see and interact with critical patient data all while visualizing and caring for the patient. In an exclusive podcast interview with Medtech Insight, Masimo chairman and CEO Joe Kiani and Atheer founder and chief technology officer Soulaiman Itani discuss these technologies, why they decided to combine patient monitoring with virtual reality and what's next for these devices.

Download the entire podcast directly from here

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.